Project Grant HT94252510696
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$592K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
The Defense Health Agency has awarded a $766,079 Project Grant to the Icahn School of Medicine at Mount Sinai to conduct research under the Military Medical Research and Development program (CFDA 12.420). The grant, which runs from September 1, 2023 to August 31, 2026, aims to "UNRAVEL THE EVOLUTION OF MELANOMA WITHIN THE HOST IMMUNE ECOSYSTEM." As a leading private medical research institution, the Icahn School of Medicine at Mount Sinai has a history of providing a wide range of...
The Project Grant award of $202,800 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award supports advanced biomedical research conducted by the Icahn School of Medicine at Mount Sinai (ISMMS) to investigate "Spatial Copy Number and Morphologic Alterations in Early Lung Carcinogenesis". The research project aims to transform healthcare for military service members, veterans, and the broader public by advancing the...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is providing $1,014,000.00 to the Icahn School of Medicine at Mount Sinai to conduct research aimed at creating cures for patients with Langerhans cell histiocytosis. The research, which is scheduled to take place from September 1, 2024 to August 31, 2028, will leverage the institution's expertise in areas such as cancer biology, immunology, and clinical...
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $507,000 Project Grant to the Icahn School of Medicine at Mount Sinai. The grant, effective from Sep 1, 2025 to Aug 31, 2027, will support research to investigate tumor-intrinsic epigenetic mechanisms modulating antitumor immune responses in metastatic prostate cancer. As a leading academic medical center, the Icahn School of Medicine at Mount Sinai has a strong track record of...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $633,750.00 to the Icahn School of Medicine at Mount Sinai to study the "Interplay Between Sensory Neurons and NK Cells During Breast Cancer Metastatic Dormancy." The 3-year award, running from August 1, 2025 to July 31, 2028, will support advanced biomedical research to transform healthcare for military service members, veterans, and the...
The Icahn School of Medicine at Mount Sinai will receive $1,521,002 under a three-year Project Grant award from the Defense Health Agency. The grant will support research from August 1, 2023 to July 31, 2026 under the Military Medical Research and Development program (CFDA 12.420). Specifically, the funding will enable research to determine the contribution of lineage intermediate tumor cells during progression to T-SCNC. This work aligns with the Military Medical Research and Development...
The Icahn School of Medicine at Mount Sinai will receive $760,500 from the Defense Health Agency under a three-year Project Grant award through the Military Medical Research and Development program (CFDA 12.420). The grant will fund research to functionally identify high-dimensional driver combinations in basal-like breast cancer. Through February 1, 2023 to January 31, 2026, this award will support the Icahn School of Medicine's efforts to transform health care for service members and the...
The Icahn School of Medicine at Mount Sinai has been awarded a $591,486 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, running from September 1, 2023 to August 31, 2026, will support the development of a novel immuno-oncology pipeline for FGFR2 fusion-positive cholangiocarcinoma. The funding will enable the medical school to conduct research aimed at transforming health care for service members and the...
This $505,270.00 federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research at the Icahn School of Medicine at Mount Sinai to investigate the impact of reprogrammed PIK3R1-insulin-glucose metabolism pathway in lethal prostate cancer. The research aims to develop new therapeutic strategies, with a project period from September 30, 2025 to September 29, 2027. As a leading academic medical...
The Icahn School of Medicine at Mount Sinai (ISMMS) was awarded a $676,000 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "EPIGENETIC STUDIES OF CANDIDATE CELLS OF ORIGIN FOR DIFFUSE MIDLINE GLIOMA," is for a research project spanning from September 1, 2024, to August 31, 2026. The funding will support ISMMS's investigation into epigenetic factors that contribute to the development of diffuse...